A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

Solid Tumors Clinical Trial

Official title:

A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02279433
• Other study ID #: DS6051-A-U101
• Status: Completed
• Phase: Phase 1
• Start date: September 2014
• Est. completion date: March 2019

Study information

• Verified date: July 2020
• Source: AnHeart Therapeutics Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D). In addition, this study will also assess the pharmacokinetic (PK)/pharmacodynamic (PD) profiles and preliminary efficacy of DS-6051b.

Description:

The Dose Escalation part (Part 1) of this study will evaluate safety and tolerability, and determine the tentative RP2D. Plasma exposure of DS-6051a and the exposure - QT interval prolongation relationship will also be assessed. Approximately 30 subjects with advanced solid tumors harboring ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement, neuroendocrine carcinoma, or with advanced solid tumors and tumor-induced pain will be enrolled.

The Food Effect (FE) part of this study is to determine the effect of food on the PK of DS-6051a following administration of a single oral dose of DS-6051b. The safety and tolerability of DS-6051b administered with or without food will also be assessed.

After the safety profile of DS-6051b is adequately evaluated, the Dose Expansion part (Part 2) will be initiated to further assess the safety and tolerability, and preliminarily evaluate the efficacy of DS-6051b at the tentative RP2D. Approximately 40 cancer subjects carrying a ROS1 or NTRK1, NTRK2, or NTRK3 rearrangement will be enrolled.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: March 2019
• Est. primary completion date: March 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically or cytologically confirmed diagnosis of advanced solid tumors that have relapsed from or are refractory to standard treatment or for which no standard treatment is available

2. Part 1 Dose Escalation subjects must meet 1 of the following criteria:

• Solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement

• Neuroendocrine tumors

• Solid tumors with tumor-induced pain

3. Part 2 Dose Expansion subjects must meet 1 of the following criteria:

• NSCLC with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement

• k-RAS wild-type CRC with documented NTRK1, NTRK2, or NTRK3 rearrangement

• Other solid tumors with documented ROS1, NTRK1, NTRK2, or NTRK3 rearrangement

• Pulmonary LCNEC;

4. Male or female =18 years of age

5. Eastern Cooperative Oncology Group performance status 0 to 1

6. Adequate organ function

7. Adequate blood clotting function

8. Women of childbearing potential must have a negative pregnancy test

9. Willingness to provide archival tumor samples

10. Other inclusion criteria may apply

Exclusion Criteria:

1. Hematological malignancies

2. Known positive HIV infection, or active hepatitis B or C infection

3. Comorbidity that would interfere with therapy

4. Receipt of an allogeneic bone marrow or allogeneic stem cell transplant

5. Concomitant medical condition that would increase the risk of toxicity, in the opinion of the Investigator or Sponsor

6. History of myocardial infarction and unstable angina within 6 months before study drug treatment; symptomatic congestive heart failure (Congestive Heart Failure New York Heart Association Class III or IV); congenital long QT syndrome; or ventricular arrhythmias defined as grade =2 according to NCI CTCAE, v4

7. Clinically active primary central nervous system tumors or brain metastases with the exception of subjects with glioblastoma multiform that carry ROS1 rearrangement

8. Unresolved toxicities from previous anticancer therapy

9. Systemic treatment with anticancer therapy within 3 weeks before study drug treatment

10. Therapeutic radiation therapy or major surgery within 4 weeks before study drug treatment or palliative radiation therapy within 2 weeks before study drug treatment

11. Participation in a therapeutic clinical study within 3 weeks for biological treatments, and within 2 weeks or 5 half-lives, whichever is longer, for small molecule agents, before study drug treatment

12. Concomitant treatment with strong inhibitors or inducers of CYP3A4 and P-glycoprotein

13. Clinically significant malabsorption syndrome or other gastrointestinal disease that would impact drug absorption

14. QTcF values higher than 450 ms at screening

15. Breastfeeding

16. Other exclusion criteria may apply

Related Conditions & MeSH terms

• Solid Tumors

Intervention

Drug:
• DS6051b
DS-6051b 50 mg and 200 mg capsules for oral administration

Locations

Country	Name	City	State
United States	Dana Farber Cancer Inst.	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	New York University	New York	New York
United States	Chao Family Comprehensive Cancer Center of	Orange	California
United States	South Texas Accelerated Research Therapeutics	San Antonio	Texas
United States	HonorHealth Research Institute	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
AnHeart Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1: Number of participants with dose-limiting toxicities		within 21 days following the first dose of treatment
Primary	Tumor response	Tumor response will be assessed using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.	up to 2 years
Secondary	Maximum concentration (Cmax) for DS-6051a		At Days 1 and 15 of Cycle 1 (21 days)
Secondary	Time to maximum concentration (Tmax) for DS-6051a		At Days 1 and 15 of Cycle 1 (21 days)
Secondary	Area under the concentration-time curve from time zero to t (AUC0-t) for DS-6051a		At Days 1 and 15 of Cycle 1 (21 days)
Secondary	Change from baseline in QTc interval	ECGs performed to assess QTc interval (ms) at baseline and on study treatment and at the end of treatment visit.	within 2 years